CLAIMS.

 Use of a compound according to Formula I in the manufacture of a medicament for the treatment of a disease caused by a disturbance in the activity of the androgen receptor, wherein Formula I is defined as:

$$R_{6} \xrightarrow{\overset{R_{7}}{Z}} X^{R_{3}} \xrightarrow{R_{4}} Y$$

Formula I

in which;

R₁ and R₂ are the same or different and independently selected from the group consisting of; hydrogen, halogen, C₁-C₁₀ alkyl, C₁-C₁₀ substituted alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₁-C₁₀ alkynyl, C₁-C₁₀ alkynyl, C₁-C₁₀ alkynylthio, C₁-C₁₀ alkynylthio, C₁-C₁₀ alkynylthio, C₁-C₁₀ alkynylthio, C₁-C₁₀ arylthio, C₁-C₁₀ alkylsulphone, C₁-C₁₀ alkylsulphone, C₁-C₁₀ alkylsulphoxide, C₁-C₁₀ alkynylsulphoxide, C₁-C₁₀ alkynylsulphoxide, C₁-C₁₀ alkylsulphoxide, C₁-C₁₀ aryl, or C₂-C₂₀ heteroaryl, optionally substituted with 0, 1, 2 or 3 groups of R³ which groups may be the same or different; or R₁ and R₂ may together form a C₂-C₁₀ eycloalkyl group;

 R_3 and R_4 are the same or different and independently selected from hydrogen, halogen, C_1 – C_{20} alkyl, C_3 – C_7 cycloalkyl, C_2 – C_4 alkenyl, C_2 – C_4 alkynyl, C_1 – C_4 alkyny, C_1 – C_4 alkynyl, C_1 – C_4 alkynylthio, C_1 – C_4 alkynylthio, C_1 – C_4 alkynylthio, C_1 – C_4 alkynylthio, C_1 – C_{10} alkylsulphone, C_1 – C_{10} alkylsulphone, C_1 – C_{10} alkylsulphoxide, C_1 – C_{10} alkenylsulphoxide, C_1 – C_{10} alkynylsulphoxide, C_4 – C_{10} arylsulphoxide, C_1 – C_{10} alkylarylsulphoxide, C_1 – C_{10} alkylarylsulphoxide, C_1 – C_{10} alkylarylsulphoxide, C_1 – C_{10} alkylarylsulphoxide, C_1 – C_1 0 alkylarylsulphoxide, C_1 0 alkylarylsulp

 R_3 is chosen from the group consisting of, nitro, cyano, -CH₂CN, -COMe, acetic acid, halogen, sulphonic acid, -SO₂CH₃, aldehyde, carboxylic acid or ester, phosphonic acid or ester.

SUBSTITUTE SHEET (RULE 26)

 R_4 is chosen from the group consisting of; hydrogen, $C_1\text{-}C_3$ alkyl, halogen, CN, CO₂H, CHF₃, CH₂F or CF₃;

R₇ is chosen from the group consisting of; H, halogen or C₁-C₅ alkyl;

 R_8 is chosen from the group consisting of; hydrogen, C_1 - C_5 alkyl, halogen, CHF2, CH2F or CF3;

X is chosen from the group consisting of; –NH-, -O-, -S-, -SO-, -SO₂, -Se-, -Te- or –S-S-

Y is chosen from the group consisting of; hydrogen, hydroxy, -CH2OH, methoxy, NH₂, unbranched, branched or cyclic C_1 - C_3 alkyl, unbranched, branched or cyclic $-NH(C_1$ - C_3); unbranched, branched or cyclic $N(C_1$ - C_3), -NH(C_6 aryl), -N(C_6 aryl), -NH(C_1 - C_1 0 heteroaryl), and -N(C_5 - C_1 0 heteroaryl), cyclic heteroaryl wherein any of said aryl or heteroaryl groups are optionally substituted with up to 3 groups of R^a which groups may be the same or different;

Z is chosen from the group consisting of; C, N, or O;

R* represents a member selected from: hydrogen, halogen, -CN, OH, CO₂H, CHO, NO₂, -NH₂, -NH(C₁C₄); N(C₁.C₄)₂, -NH(C₆ aryl), -N(C₆ aryl)₂, -NH(C₅C₁₀ heteroaryl), and -N(C₅.C₁₀ heteroaryl)₂; or a pharmaceutically acceptable salt thereof.

- Use according to claim 1, wherein R₁ or/and R₂ are H, (S)-methyl, methyl, (R)-ethyl, (S)-ethyl, ethyl, (R)-propyl, (S)-propyl, propyl, (S)-butyl, (S)-1-methyl-propyl, (S)-2-methyl-propyl, (R)-isopropyl, (S)-isopropyl, isopropyl, cyclopentyl, -(CH₂)₂SMe, (R)-CH₂SCH₂Ph, (S) -benzyl, 4-chloro-benzyl, (S)-3-methyl-1-H-indole or (S)-phenyl;
 - Use according to either of the preceding claims wherein R₃ is chosen from
 the group consisting of; hydrogen, methyl, ethyl, phenyl, 3-hydroxy phenyl,
 4-hydroxy phenyl, or forms a keto group together with R₄.
 - Use according to any of the preceding claims wherein R₄ is H, methyl, or forms a keto group together with R₃.
 - 5. Use according to any of the preceding claims wherein R_6 is NO₂, CN, CH₂CN or CO₂H:
 - Use according to any of the preceding claims wherein R₆ is Me, or CF₃;
 - Use according to any of the preceding claims wherein R₂ is H or Me;
 - Use according to any of the preceding claims wherein R₈ is H or methyl;
 - Use according to any of the preceding claims wherein X is NH;
 - Use according to any of the preceding claims wherein Y is H, -OH, -OMe, -N (CH₂CH₃)₂, piperidine, or 4-nitro-2-ylamino;
 - 11. Use according to any of the preceding claims wherein Z is CR2 or N;
 - Use according to any of the preceding chains wherein the compound is chosen from the group consisting of;
 - 2-Methyl-2-(4-mitro-3-trifluoromethyl-phenylamino)-propan-1-ol;
 - [1-(4-Nitro-3-trifluoromethyl-phenylamino)-cyclopentyl]-methanol;
 - (S)-2-(4-Nitro-3-trifluoromethyl-phenylamino)-3-phenyl-propan-1-0l;

- (S)-2-(4-Nitro-3-trifluoromethyl-phenylamino)-butan-1-ol;
- 2-Methyl-2-(3-hydroxy-4-nitro-phenylamino)-propan-1-ol;
- [1-(3-Methyl-4-nitro-phenylamino)-cyclopentyl]-methanol;
- (S)-2-(3-Methyl-4-nitro-phenylamino)-butan-1-ol;
- 2-Methyl-2-(6-methyl-5-nitro-pyridine-2-ylamino)-propan-1-ol;
- [1-(6-Methyl-5-nitro-pyridine-2-ylamino)-cyclopentyl]-methanol;
- (S)-2-(6-Methyl-5-nitro-pyridin-2ylamino) 2-phenyl-ethanol;
- (S) -2-(6-Methyl-5-nitro-pyridine-2-ylamino)-3-phenyl-propan-1-ol;
- (S)-2-(6-Methyl-5-nitro-pyridin-2-ylamino)-butan-1-ol;
- (DL) -3-(4-Chloro-phenyl)-2-(6-methyl-5-nitro-pyridin-2-ylamino)- -propan-1-ol;
- (S)-2-(6-Methyl-5-nitro-2-pyridin-2-ylamino)-propionic acid;
- (S)-2-(6-Methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol;
- 2-(2,3-Dimethyl-4-nitro-phenylamino)-2-mehtyl-propan-1-ol;
- (S)-2-(3,5-Dimethyl-4-nitro-phenylamino)-butan-1-ol;
- 4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-trifluoromethyl-benzonitrile;
- 4-(1-Hydroxymethyl-cyclopentylamino)-2-trifluoromethyl-benzonitrile;
- (S)-4-(1-Hydroxymethyl-cyclopentylamino)-2-trifluoromethyl-benzonitrile;
- (R)-4-(1-Hydroxymethyl-butylamino)-2-trifluoromethyl-benzonitrile;
- (S)-4-(1-Hydroxymethyl-butylamino)-2-trifluoromethyl-benzonitrile;
- [4-((S)-1-Hydroxymethyl-butylamino)-2-trifluoromethyl-phenyl]-acetonitrile;
- [4-((R)-1-Hydroxymethyl-butylamino)-2-trifluoromethyl-phenyl]-acetonitrile;
- [4-((S)-1-Hydroxymethyl-3-methyl-butylamino)-2-trifluoromethyl-phenyl]-acetonitrile;
- 4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-methyl-benzonitrile;
- 6-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-methyl-nicotinonitrile;
- $\hbox{$4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2,3-dimethyl-benzonitrile;}$

and compounds having the formula:

$$R_6$$
 Z R_9 O_2N

in which R_9 , R_6 and Z are as defined in the following table:

R9	R6	Z
н Х ^N м он	CF ₃	сн
HO	CF₃	СН
Х ^N OH	CF ₃	СН
HO KNH	CF ₃	СН
HO HN X	CF ₃	СН
HO	CF ₃	СН
HN HO	CF ₃	СН
HO OH	CF ₃	СН

R9	R6	z		
₹ ^N ·oh	CF,	СН		
HO HO HO	CF ₃	СН		
>s → OH	CF ₃	СН		
OH OH	CF ₃	сн		
S NH OH	CF ₃	СН		
→ NH ≻ NH	CF ₃	СН		
HO Y	CF,	СН	·	
HO HO H	CF ₃	сн		
N t	CF ₃	СН		

R9	R6	Z
¥"~~_o~	CF ₃	СН
× _{MH}	CF ₃	СН
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	CF ₃	СН
×NH	CF ₃	сн
OF NH NH	CF ₃	сн
HO N X	CF ₃	СН
→ N _N , OH	СН3	N
но	СН3	N
X _N ✓ oн	СН3	N

R9	R6	Z	
- R3			
HO YNH	СН	N	
но Ж	СЊ	N	
HO	СЊ	N	
HN NO	СЊ	N	
X ^N → OH	СЊ	N	
NH OH	СН	. N	
HO NO	СЊ	N	
J _C NH OH	СЊ	N	
S NH OH	СН	N	

R9	R6	Z
V _{NH} OH	CH ₃	N
HO KING S	СН3	N
× ^{NH} OH	СН3	N
OH H	СН3	N
HO	СН3	N
* ^h ~~~	СН3	N
×××	СНз	N
Z _{MH}	СН3	N
HO NA	СН3	N
≿ ^н он	СН	СН

					1
· R9	R6	Z			l
но Т	СН3	СН			
H Non	СН₃	СН			
но	СНз	СН			
Ho ∕ NH	СН₃	СН			
но	СН	СН			
HN HO	СН	СН			_
УКИ ОН	. снь	СН			
S OH	СН	СН			
→ NH OH	СН	сн			
→ OH	СН3	СН	<u> </u>		
HO HN XX	СН	СН			
	-		+	+	-
	1				_
	\pm				-
					_
					_
	-		+		-

R9	R6	Z			
~~*	СН	СН			
·LOV	СН	СН			
		=			=
		=	+=	=	
	\equiv			=	\pm
		\pm			

- 4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-methyl-benzoic acid;
- (6-Methyl-5-nitro-2-pyridin-2-ylamino)-butionic methyl ester,
- 2-Methyl-N-(6-methyl-5-nitro-pyridin-2-yl amino)-propan-2-ol;
- 4-(R)-2-Hydroxy-1-methyl-ethylamino)-2-trifluoromethyl-benzonitrile
- 4-(R)-1-Furan-2-ylmethyl-2-hydroxy-ethylamino)-2-trifluoromethyl-benzonitrile
- (R)-3-Furan-2-yl-2-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol
- 2-(6-Methyl-5-nitro-pyridin-2-ylamino)-heptan-1-ol
- 3-Cyclopenty1-2-(6-methy1-5-nitro-pyridin-2-ylamino)-propan-1-o1
- 2-(6-Methyl-5-nitro-pyridin-2-ylsulfanyl)-ethanol
- [1-{4-Fluoro-3-methyl-phenylamino}-cyclopentyl}-methanol
- 1-[4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-trifluoromethyl-phenyl}-ethanone
- 1-[4-((S)-1-Hydroxymethyl-3-methyl-butylamino)-2-trifluoromethyl-phenyl}-ethanone

- 1-[4-(1-Hydroxymethyl-cyclopentylamino)-2-trifluoromethyl-phenyl]-ethanone
 - [1-(4-Methanesulfonyl-3-methyl-phenylamino)-cyclopentyl]-methanol
- 2.2-Dimethyl-3-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol
- 2. 2-Dimethyl-3-(3-methyl-4-nitro-phenylamino)-propan-1-ol
- 4-((R)-1-Benzylsulfanylmethyl-2-hydroxy-ethylamino)-2-trifluoromethyl-benzonitrile
- (R)-2-(6-Methyl-5-nitro-pyridin-2-ylamino)-3-phenylmethanesulfinyl-propan-1-ol
- $4-(\{R\})-2-Rydroxy-1-phenylmethanesulfinylmethyl-ethylamino)-2-trifluoromethyl-benzon itrile$
- [1-(4-Nitro-phenylamino)-cyclopentyl]-methanol
- (S)-2-(4-Nitro-phenylamino)-pentan-1-ol
- (S)-4-Methyl-2-(4-mitro-phenylamino)-pentan-1-ol
- [1-(2-Bromo-4-nitro-phenylamino)-cyclopentyl]-methanol
- (S)-2-(2-Bromo-4-nitro-phenylamino)-pentan-1-ol
- (S) -2- (2-Bromo-4-nitro-phenylamino) -4-methyl-pentan-1-ol or a pharmaceutically acceptable salt thereof.
- 13. Use of compound according to claim 1, wherein R_1 or R_2 is a C_0 - C_{10} arythio comprising an aryl-substituted sulfur-containing C_1 - C_{10} alkyl group.
- 14. Use of a compound according to claim 1, wherein $\frac{1}{7}n$ R_1 or R_2 the alkylsulfur is substituted with a C_6 aryl group.
- A pharmaceutical composition containing a compound as defined in Formula I of any preceding claim.

 Use according to claim 1 wherein the disease is caused by an increase in androgen receptor activity.

17. Use according to any of claims 1-14 or 16 wherein the disease is chosen from the group consisting of, prostate cancer, lipid abnormalities, cardiovascular disease and psychological abnormalities, male pattern baldness (alopecia), benign prostatic hyperplasia (BPH) and acne, hirsutism, amenorrha, hypogonadism, anemia, diabetes, defects in spermatogenesis, cachexia, osteoporosis, osteopenia, and muscle wasting.

18. A compound as defined by Formula I:

$$\begin{matrix} R_6 \\ Z \\ R_5 \end{matrix} \begin{matrix} R_7 \\ R_1 \end{matrix} \begin{matrix} R_2 \\ R_2 \end{matrix} \begin{matrix} R_4 \\ R_2 \end{matrix}$$

Formula I

in which;

 R_1 and R_2 are the same or different and independently selected from the group consisting of; hydrogen, halogen, C_1 - C_1 - C_1 alkyl, C_1 - C_1 -

R₃ and R₄ are the same or different and independently selected from hydrogen, halogen, C₁-C₂₀ alkyl, C₂-C₇ cycloalkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₁-C₄ alkoxy, C₁-C₄ alkenyl, C₁-C₄ alkynythio, C₁-C₄ alkynythio, C₁-C₄ alkynythio, C₁-C₁₀ alkynylsulphone, C₁-C₁₀ alkynylsulphone, C₁-C₁₀ alkynylsulphoxide, C₂-C₁₀ alkynylsulphoxide, C₃-C₁₀ arylsulphoxide, C₄-C₁₀ alkynylsulphoxide, C₄-C₁₀ arylsulphoxide, C₄-C₁₀ arylsulphoxide, C₄-C₁₀ alkylarylsulphoxide, C₄-C₁₀ alkylarylsulphoxide, C₄-C₁₀

alkylarylsulphoxide, C_0 - C_1 s aryl, C_2 - C_2 heteroaryl optionally substituted with 0, 1, 2 or 3 groups of R^4 which groups may be the same or different; or can together form a keto group;

 R_s is chosen from the group consisting of; nitro, cyano, -CH₂CN, -COMe, acetic acid, halogen, sulphonic acid, -SO₂CH₃, aldehyde, carboxylic acid or ester, phosphonic acid or ester;

 R_6 is chosen from the group consisting of, hydrogen, C_1 - C_5 alkyl, halogen, CN, CO_2H , CHF_5 , CH_2F or CF_5 ;

R₇ is chosen from the group consisting of; H, halogen or C₁-C₅ alkyl;

 R_4 is chosen from the group consisting of; hydrogen, $C_1\text{-}C_5$ alkyl, halogen, CHF_2 , CH_2F or CF_3 ;

X is chosen from the group consisting of; –NH-, -O-, -S-, -SO-, -SO₂, -Se-, -Te- or –S-S-

Y is chosen from the group consisting of; hydrogen, hydroxy, -CH2OH, methoxy, NH₂, unbranched, branched or cyclic C₁-C₅ alkyl, unbranched, branched or cyclic -NH(C₁.C s); unbranched, branched or cyclic N(C₁-C₅)₂, -NH(C₅aryl), -N(C₅aryl)₂, -NH(C₁-C₁₀ heteroaryl), and -N(C₅C₁₀ heteroaryl)₂, C₅C₁₀ heteroaryl wherein any of said aryl or heteroaryl groups are optionally substituted with up to 3 groups of Rⁿ which groups may be the same or different;

Z is chosen from the group consisting of; C, N, or O;

 R^a represents a member selected from: hydrogen, halogen, -CN, OH, CO₂H, CHO, NO₂s. -NH₂, -NH(C₁C₄); N(C₁C₄)₂, -NH(C₆ aryl), -N(C₆ aryl)₂, -NH(C₅C₁₀ heteroaryl), and -N(C₅C₁₀ heteroaryl)₂; or a pharmaceutically acceptable salt thereof.

with the proviso that the compound is not:

- 19. A compound according to claim 18, wherein R₁ or/and R₂ are H, (S)-methyl, methyl, (R)-ethyl, (S)-ethyl, (thyl, (R)-propyl, (S)-propyl, propyl, (S)-butyl, (S)-1-methyl-propyl, (S)-2-methyl-propyl, (R)-isopropyl, (S)-isopropyl, isopropyl, cyclopentyl, -(CH₂)₂SMe, (R)-CH₂SCH₃Ph, (S)-benzyl, 4-chloro-benzyl, (S)-3-methyl-1-H-indole or (S)-phenyl;
- 20. A compound according to either of claims 18 and 19, wherein R₃ is chosen from the group consisting of, hydrogen, methyl, ethyl, phenyl, 3-hydroxy phenyl, 4-hydroxy phenyl, or forms a keto group together with R₄.
- 21. A compound according to any of claims 18-20, wherein R_i is H, methyl, or forms a keto group together with R_3 .
- 22. A compound according to any of claim 18-21, wherein R_8 is NO₂, CN, CH₂CN or CO₂H;
- 23. A compound according to any of claims 18-22, wherein R_6 is Me, or CF_3 .
- 24. A compound according to any of claims 18-23, wherein R_7 is H or Me.
- 25. A compound according to any of claims 18-24, wherein Re is H or methyl.
- 26. A compound according to any of claims 18-25, wherein X is NH.
- A compound according to any of claims 18-26, wherein Y is H, -OH, -OMe, -N (CH₂CH₃)₂, piperidime, or 4-nitro-2-ylamino.
- 28. A compound according to any of claims 18-27, wherein Z is CR7 or N.
- 29. A compound according to any of claims 18-28, wherein the compound is chosen from the group consisting of:

2-Methyl-2-(4-mino-3-trifluctomethyl-phenylamino)-propan-1-05 .

[1-(4-Nitro-3-triffnorometryl-phenylamino)-cyclopentyl]-methanol;

(S)-2-(4-Nitro-3-triflumomethyl-phenylamino)-3-phenyl-propan-1-0l;

(S)-2-(4-Nitro-3-trifluoromethyl-phenylamino)-butan-1-ol;

2-Methyl-2-(3-hydroxy-4-nitro-phenylamino)-propan-1-ol;

[1-(3-Methyl-4-nitro-phenylamino)-cyclopentyl]-methanol;

[1-(3-tytemyr--muo-pantyamano) eyes-pensys] meaning

(S)-2-(3-Methyl-4-nitro-phenylamino)-butan-1-ol;

2-Methyl-2-(6-methyl-5-nitro-pyridine-2-ylamino)-propan-1-ol;

[1-(6-Methyl-5-nitro-pyridine-2-ylamino)-cyclopentyl]-methanol;

(S)-2-(6-Methyl-5-nitro-pyridin-2ylamino) 2-phenyl-ethanol;

(S) -2-(6-Methyl-5-nitro-pyridine-2-ylamino)-3-phenyl-propan-1-ol;

(S)-2-(6-Methyl-5-nitro-pyridin-2-ylamino)-butan-1-ol;

(DL) -3-(4-Chloro-phenyl)-2-(6-methyl-5-nitro-pyridin-2-ylamino)- -propan-1-ol;

(S)-2-(6-Methyl-5-nitro-2-pyridin-2-ylamino)-propionic acid;

(S)-2-(6-Methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol;

2-(2,3-Dimethyl-4-nitro-phenylamino)-2-mehtyl-propan-1-ol;

(S)-2-(3.5-Dimeftyl-4-nitro-phenylamino)-butan-1-ol;

4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-trifluoromethyl-benzonitrile;

4-(1-Hydroxymethyl-cyclopentylamino)-2-trifluoromethyl-benzonitrile;

(S)-4-(1-Hydroxymethyl-cyclopentylamino)-2-trifluoromethyl-benzonitrile;

(R)-4-(1-Hydroxymethyl-butylamino)-2-trifluoromethyl-benzonitrile;

(S)-4-(1-Hydroxymethyl-butylamino)-2-trifluoromethyl-benzonitrile;

[4-((S)-1-Hydroxymethyl-butylamino)-2-trifluoromethyl-phenyl]-acetonitrile;

[4-((R)-1-Hydroxymethyl-butylamino)-2-trifluoromethyl-phenyl]-acetonitrile;

[4-((S)-1-Hydroxymethyl-3-methyl-butylamino)-2-trifluoromethyl-phenyl]-acetonitrile;

4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-methyl-benzonitrile;

6-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-methyl-nicotinonitrile;

4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2,3-dimethyl-benzonitrile; and compounds having the formula:

in which Ro, Ro and Z are as defined in the following table:

R9	R6	Z
Х ^и , ~~ он	CF ₃	СН
HO HIN X	CF ₃	СН
Х _и ∕он	CF ₃	СН
HO XMH	CF ₃	СН
HO	CF ₃	сн
HO	CF ₃	СН
HN HO	CF ₃	СН
HO OH	CF ₃	СН

R9	R6	z	
₹ ^N OH	CF ₃	СН	
HO HN HN	CF ₃	СН	
S OH	CF ₃	СН	
→ OH	CF ₃	сн	
S NH	CF ₃	СН	
> NH OH	CF ₃	СН	
BO BN	CF ₃	сн	
HO HO	CF ₃	СН	
\text{\tin}\ext{\tin}\tint{\text{\text{\text{\text{\text{\text{\text{\text{\text{\tin}\tint{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\texi}\text{\text{\texi}\tint{\text{\text{\text{\text{\text{\text{\texi}}\tint{\text{\tin}\tint{\text{\text{\text{\texi}\tint{\text{\text{\texi}\text{\texitt{\text{\text{\text{\texi}\tint{\text{\texi}\tint{\text{\ti}\tint{\tinit}\tint{\text{\ti}\tint{\text{\texi}\til\text{	CF ₃	СН	

R9	R6	Z
ку	- 10	~~
¥"~~o~	CF ₃	СН
X _{NH}	CF3	СН
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	CF ₃	СН
×NH	CF ₃	СН
O N NH	CF ₃	СН
но Но н х	CF ₃	СН
F, N, N, OH	СН3	N
но Дим	СН3	N .
X _N → OH	СН3	N

R9	R6	Z
но Хин	СН	И
но Х	СЊ	N
HO	СЊ	и
HN HO	СЊ	N
Х	СН	N
он Жин	СН	N
HO NO	СН	N
¥,NH OH	СЊ	И
`з	С₩	N

R9	R6	Z
¥ ^{NH} OH	СН3	N
S NH OH	СН₃	N
× ^{NH} OH	СН3	N
OH H	СН₃	N
HO	СН3	N
*!~~~	CH ₃	N
×NH	СН	N
₹ ^{NH}	СН₃	N
HO NY	СНз	N
≯ ^N → OH	СН3	СН

R9	R6	Z	├	-		\dashv	
но Жин	СН3	СН					
XN OH	СН3	сн					
но Ниму	СН₃	СН					
HO KNH	СНз	СН					
HO K	СН₃	СН					
HO HO	СНз	СН					
X,NH OH	. СН	СН					
S OH	СН	СН					
→ OH	СН	CI	1				
→ Indian	СН	CI	ı.				
но Ж	СН	3 C	H				
				匚		_	_
	\pm	\Rightarrow		\vdash	_	\vdash	_
	\pm		_	\pm		=	_
				\vdash	_	\pm	_
				\vdash		-	_

R9	R6	Z			
~;*×	СН3	СН			
	СН	сн			
		=	 	+=	=
			E		+
		\equiv			=
	\pm		\pm	二	\pm

- 4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-methyl-benzoic acid;
- (6-Methyl-5-nitro-2-pyridin-2-ylamino)-butionic methyl ester;
- 2-Methyl-N-(6-methyl-5-nitro-pyridin-2-yl amino)-propan-2-ol;
- 4-(R)-2-Hydroxy-1-methyl-ethylamino)-2-trifluoromethyl-benzonitrile
- 4-(R)-1-Furan-2-ylmethyl-2-hydroxy-ethylamino)-2-trifluoromethyl-benzonitrile
- (R)-3-Furan-2-yl-2-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol
- 2-(6-Methyl-5-nitro-pyridin-2-ylamino)-heptan-1-ol
- 3-Cyclopentyl-2-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol
- 2-(6-Methyl-5-nitro-pyridin-2-ylsulfanyl)-ethanol
 - [1-(4-Fluoro-3-methyl-phenylamino)-cyclopentyl]-methanol
- 1-[4-(2-Hydroxy-1,1-dimethyl-ethylamino)-2-trifluoromethyl-phenyl]-ethanone
- 1-[4-((S)-1-Hydroxymethyl-3-methyl-butylamino)-2-trifluoromethyl-phenyl}-ethanone

- 1-[4-(1-Hydroxymethyl-cyclopentylamino)-2-trifluoromethyl-phenyl]-ethanone
- [1-(4-Methanesulfonyl-3-methyl-phenylamino)-cyclopentyl]-methanol
- 2,2-Dimethyl-3-(6-methyl-5-nitro-pyridin-2-ylamino)-propan-1-ol
- 2, 2-Dimethyl-3-(3-methyl-4-nitro-phenylamino)-propan-1-ol
- ${\tt 4-(\{R\}-1-Benzyl sulfanyl methyl-2-hydroxy-ethyl amino)-2-trifluoromethyl-benzonitrile}$
- (R)-2-(6-Methyl-5-nitro-pyridin-2-ylamino)-3-phenylmethanesulfinyl-propan-1-ol
- 4-(R)-2-Hydroxy-1-phenylmethanesulfinylmethyl-ethylamino)-2-trifluoromethyl-benzon
 - (1-(4-Nitro-phenylamino)-cyclopentyl]-methanol
 - (S)-2-(4-Nitro-phenylamino)-pentan-1-ol
 - (S)-4-Methyl-2-(4-nitro-phenylamino)-pentan-1-ol
 - [1-(2-Bromo-4-nitro-phenylamino)-cyclopentyl]-methanol
 - (S)-2-(2-Bromo-4-nitro-phenylamino)-pentan-1-ol
 - (S)-2-(2-Bromo-4-nitro-phenylamino)-4-methyl-pentan-1-ol
 - 30. A compound according to any of claims 18-29, wherein R_1 or R_2 is a C_6 - C_{10} arythio comprising an aryl-substituted sulfur-containing C_1 - C_{10} alkyl group.
 - 31. A compound according to any of claims 18-30, wherein in R_1 or R_2 the alkylsulfur is substituted with a C_6 aryl group.